Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
201-220 of 1,782 trials

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyInternal Medicine

Early Breast Cancer: Ribociclib with Endocrine Therapy

We are studying the effects of ribociclib combined with endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. This trial aims to understand how well this treatment works and its safety.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Flu Vaccine Study for Adults 65 and Older

We are testing a new adjuvanted flu vaccine to see if it works as well as a standard flu vaccine in preventing influenza in older adults. The study will also evaluate safety and immune response to the vaccine.

Influenza6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious Diseases

Heart Failure Treatment: Carvedilol vs. Metoprolol

We are comparing two heart medications to see which one may better help patients with heart failure and reduced ejection fraction. This study involves patients who need beta-blocker treatment for their condition.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

TAK-330 for Reversing Blood Thinner Effects in Urgent Surgery

We are studying whether TAK-330 can effectively reverse the effects of certain blood thinners in patients needing urgent surgery. This trial compares TAK-330 to the standard treatment to see which works better.

Patients on Factor Xa Inhibitors Needing Urgent Intervention≤3 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Colitis from Cancer Treatment: The iCaD Study

We are comparing a new treatment combining infliximab with corticosteroids for severe colitis caused by immune checkpoint inhibitors. This study aims to see if this combination is more effective than corticosteroids alone.

Immune Checkpoint Inhibitor Related Colitis≤3 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Advanced Thyroid and Head and Neck Cancer: [18F]AlF-PSMA-11 PET Study

We are investigating how well [18F]AlF-PSMA-11 PET detects cancer lesions in patients with advanced thyroid and head and neck carcinoma. This study compares its effectiveness to other imaging methods.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncologyOtolaryngology

Castration-Resistant Prostate Cancer: Lutetium [177Lu] VIPIVOTIDE TETRAXETAN

We are studying a new treatment for men with castration-resistant prostate cancer to see how well it works alone and with other medications. The goal is to evaluate its effects on prostate-specific antigen (PSA) levels and overall health.

Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteOncology

Head and Neck Cancer: VB10.16 and Pembrolizumab

We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.

Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Gastrointestinal Stromal Tumor: Ripretinib vs Sunitinib

We are comparing two treatments for advanced gastrointestinal stromal tumors in patients with specific genetic mutations who have been treated before. The goal is to find out which medication may help control the disease better and improve quality of life.

Advanced Gastrointestinal Stromal TumorConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Hodgkin Lymphoma: Tislelizumab Treatment Study

We are evaluating the safety and effectiveness of tislelizumab for patients with untreated Hodgkin lymphoma who cannot undergo standard chemotherapy. This study aims to see how well this treatment works and how it is tolerated.

Classical Hodgkin LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Asymptomatic Heart Failure: TREASURE Trial

We are studying whether an ACE inhibitor can improve heart health in women with asymptomatic heart failure compared to usual care. The trial also looks at its effects on heart function, metabolic health, and quality of life.

Subclinical Heart Failure>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Fremanezumab for Pain in Complex Regional Pain Syndrome

We are studying whether fremanezumab can reduce pain in patients with Complex Regional Pain Syndrome compared to a placebo. The trial also examines how this treatment affects disease symptoms and function.

Complex Regional Pain Syndrome≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

ANCA-Associated Vasculitis: Avacopan Study

We are testing the long-term safety and effectiveness of Avacopan for people with ANCA-associated vasculitis. The study will also look at how it affects remission and overall quality of life.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineRheumatology

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology